Inhibitors of Acyl-CoA : Cholesterol Acyltransferase. II. Preparation and Hypocholesterolemic Activity of Optically Active Dibenz[b, e]oxepin-11-carboxanilides

• Published in: Chemical & pharmaceutical bulletin Vol. 44; no. 1; pp. 222 - 225
• Main Authors: KUMAZAWA, Toshiaki, YANASE, Masashi, SHIRAKURA, Shiro, OHISHI, Eiko, YAMADA, Koji, MATSUMIYA, Shigeki, KONO, Motomichi
• Format: Journal Article
• Language: English
• Published: Tokyo The Pharmaceutical Society of Japan 1996; Maruzen
• Subjects: acyl-CoA; Animals; antiatherosclerotic amide; Anticholesteremic Agents - chemical synthesis; Anticholesteremic Agents - pharmacology; Biological and medical sciences; Cholesterol - blood; cholesterol acyltransferase; Cricetinae; dibenz[b, e]oxepin-11-carboxanilide; Dibenzoxepins - chemical synthesis; Dibenzoxepins - pharmacology; Enzyme Inhibitors - chemical synthesis; Enzyme Inhibitors - pharmacology; General and cellular metabolism. Vitamins; hypocholesterolemic amide; Medical sciences; Mesocricetus; molecular modeling study; optical resolution; Pharmacology. Drug treatments; Rabbits; Stereoisomerism; Sterol O-Acyltransferase - antagonists & inhibitors; Rat; Rabbit; Oxygen heterocycle; Modeling; Prevention; Atherosclerosis; Molecular model; Bromine Organic compounds; Aromatic compound; Chemical synthesis; Enantiomer(-); Acyltransferases; Enzyme; Transferases; Rodentia; Oral administration; Enzyme inhibitor; Lagomorpha; Tricyclic compound; In vitro; Cholesterol; In vivo; Vertebrata; Mammalia; Optical resolution; Animal; Carboxamide; Antilipemic agent; Sterol O-acyltransferase
• ISSN: 0009-2363; 1347-5223
• DOI: 10.1248/cpb.44.222

In a previous paper, we reported a novel inhibitor of acyl-CoA : cholesterol acyltransferase (ACAT), 2-bromo-N-(2, 6-diisopropylphenyl)-6, 11-dihydrodibenz[b, e]oxepin-11-carboxamide (1). In this work, we prepared both enantiomers and tested them for ability to inhibit ACAT (liver microsomes from cholesterol-fed rabbits) in vitro and to decrease serum total cholesterol in cholesterol-fed golden hamsters in vivo. The precursor carboxylic acid 4 was optically resolved with cinchonidine. The obtained (-)- and (+)-4 were converted to (-)- and (+)-1 without racemization, respectively. The enantiomer (-)-1 showed potent ACAT inhibitory activity in vitro with an IC50 value of 8 nM and was approximately 10-fold more active than (+)-1. Furthermore, (-)-1 showed strong hypocholesterolemic activity in vivo, whereas (+)-1 was inactive.A molecular modeling study showed that the difference of ACAT inhibitory activity between the enantiomers was derived from the spatial alignment of the bromine.Compound (-)-1 was selected for further evaluation as KW-3033.